Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study

Abstract

Aims:

Rheumatologic disorders are characterised by inflammation and an increased risk of coronary artery disease (CAD). However, the association between rheumatologic disorders and long-term prognosis in CAD patients undergoing percutaneous coronary intervention (PCI) is unknown. Thus, we aimed to examine the association between rheumatologic disorders and long-term prognosis in CAD patients undergoing PCI.

Methods and results:

A post-hoc analysis was performed in 4605 patients (age: 63.3 ± 11.0 years; male: 76.6%) with ST-segment elevation myocardial infarction (STEMI; n = 1396), non-STEMI (n = 1541), and stable CAD (n = 1668) from the all-comer stent trials, the BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) I and II trials. We evaluated the association between rheumatologic disorders and 2-year major adverse cardiac events (MACEs; cardiac death, nonfatal myocardial infarction (MI), and target vessel revascularisation (TVR)) by Cox regression analysis. Patients with rheumatologic disorders (n = 197) were older, more often female, had a higher prevalence of renal disease, multi-vessel coronary disease, and bifurcation lesions, and had longer total stent lengths. During the 2-year follow-up, the MACE rate was 8.6% in the total cohort. After adjustment for potential confounders, rheumatologic disorders were associated with MACEs in the total cohort (adjusted hazard ratio: 1.55; 95% confidence interval (CI): 1.04–2.31) driven by the STEMI subgroup (adjusted hazard ratio: 2.38; 95% CI: 1.26–4.51). In all patients, rheumatologic disorders were associated with all-cause death (adjusted hazard ratio: 2.05; 95% CI: 1.14–3.70), cardiac death (adjusted hazard ratio: 2.63; 95% CI: 1.27–5.43), and non-fatal MI (adjusted hazard ratio: 2.64; 95% CI: 1.36–5.13), but not with TVR (adjusted hazard ratio: 0.81; 95% CI: 0.41–1.58).

Conclusions:

The presence of rheumatologic disorders appears to be independently associated with worse outcome in CAD patients undergoing PCI. This calls for further studies and focus on this high-risk group of patients following PCI.

Keywords

Coronary artery disease rheumatologic disorders prognosis revascularisation

Get full access to this article

View all access options for this article.

References

Libby

Ridker

Hansson

; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54(23): 2129–2138.

Roffi

Patrono

Collet

et al . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3): 267–315.

Berk

Weintraub

Alexander

. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990; 65(3): 168–172.

Mason

Libby

. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36(8): 482–489c.

Lindhardsen

Kristensen

Ahlehoff

. Management of cardiovascular risk in patients with chronic inflammatory diseases: current evidence and future perspectives. Am J Cardiovasc Drugs 2016; 16(1): 1–8.

Ungprasert

Charoenpong

Ratanasrimetha

et al . Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol 2014; 33(8): 1099–1104.

Lai

Chiou

et al . Outcomes of coronary artery bypass grafting in patients with inflammatory rheumatic diseases: an 11-year nationwide cohort study. J Thorac Cardiovasc Surg 2015; 149(3): 859–866.e1–2.

Van Doornum

Brand

King

et al . Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(7): 2061–2068.

Pfisterer

Bertel

Bonetti

et al .; BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J 2008; 155(4): 609–614.

10.

Kaiser

Galatius

Erne

et al .; BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363(24): 2310–2319.

11.

Jeger

Pfisterer

Alber

et al . Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitats Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J 2012; 163(2): 136–141.e1.

12.

Kaiser

Galatius

Jeger

et al .; BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2015; 131(1): 74–81.

13.

Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21(18): 1502–1513.

14.

Cutlip

Windecker

Mehran

et al .; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115(17): 2344–2351.

15.

White

Royston

. Imputing missing covariate values for the Cox model. Stat Med 2009; 28(15): 1982–1998.

16.

Gabriel

. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010; 69(Suppl. 1): i61–i64.

17.

Kitas

Gabriel

. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70(1): 8–14.

18.

Linos

Fiorentino

Lingala

et al . Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 2013; 15(1): R7.

19.

Manzi

Meilahn

Rairie

et al . Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145(5): 408–415.

20.

Niccoli

Calvieri

Flego

et al . Allergic inflammation is associated with coronary instability and a worse clinical outcome after acute myocardial infarction. Circ Cardiovasc Interv 2015; 8(8): e002554.

21.

Tamaki

Chatterjee

Langford

. Eosinophilia in rheumatologic/vascular disorders. Immunol Allergy Clin North Am 2015; 35(3): 453–476.

22.

Ribichini

Tomai

Pesarini

et al .; CEREA-DES Investigators. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). Eur Heart J 2013; 34(23): 1740–1748.

23.

Cassese

De Luca

Ribichini

et al . ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level meta-analysis of randomized trials. Atherosclerosis 2014; 237(2): 410–417.

24.

van Halm

Nielen

Nurmohamed

et al . Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66(2): 184–188.

25.

Ruff

Morrow

Jarolim

et al . Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol 2011; 38(6): 1071–1078.

26.

Wang

Dang

et al . High-sensitivity C-reactive protein predicts adverse cardiovascular events in patients with Takayasu arteritis with coronary artery involvement. Clin Rheumatol 2016; 35(3): 679–684.

27.

Tzelepis

Kelekis

Plastiras

et al . Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56(11): 3827–3236.

28.

Ciurzyński

Bienias

Irzyk

et al . Heart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci 2014; 10(3): 445–454.

29.

Dixon

Watson

Lunt

et al .; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56(9): 2905–2912.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.21 MB